Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 0329 • ACR Convergence 2021
Racial and Ethnic Disparities in Risk of End-Organ Disease Following SLE Diagnosis in a Multi-Ethnic Cohort
ALFREDO AGUIRRE¹, Andrea Seet¹, Laura Trupin², Patricia Katz¹, Kamil Barbour³, Cristina Lanata⁴, Maria Dall'Era⁵ and Jinoos Yazdany¹, ¹University of California San Francisco, San Francisco, CA, ²UC San Francisco, San Francisco, CA, ³Centers for Disease Control, Atlanta, GA, ⁴University of California San Francisco, Moss Beach, CA, ⁵University of California San Francisco, Corte Madera, CA
Background/Purpose: Racial and ethnic minorities experience a disproportionate burden of systemic lupus erythematosus (SLE) as well as earlier development of lupus manifestations as compared to…
Abstract Number: 0346 • ACR Convergence 2021
The CB-CAPillaryTM Test Kit: A Tool for Point-of-Care Assays to Measure Cell-Bound Complement Activation Products
Joseph Ahearn¹, Susan Manzi¹ and Chau-Ching Liu², ¹Allegheny Health Network, Wexford, PA, ²Allegheny Health Network, Pittsburgh, PA
Background/Purpose: Cell-bound complement activation products (CB-CAPs) have been validated as biomarkers for systemic lupus erythematosus (SLE) diagnosis, monitoring and stratification, and for identification of patients…
Abstract Number: 0495 • ACR Convergence 2021
Racial/Ethnic Differences in Multimorbidity Between Patients with Systemic Lupus Erythematosus and Comparators in a Large Nationwide US Study
Ali Duarte-Garcia¹, Herbert Heien¹, Nilay Shah¹ and Cynthia Crowson², ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Eyota, MN
Background/Purpose: Patients with systemic lupus erythematosus (SLE) have an increased burden of multimorbidity. Racial/ethnic disparities have also been associated with an increased burden of multimorbidity.…
Abstract Number: 0602 • ACR Convergence 2021
Use of a Popular Opinion Leader Model to Disseminate Information Virtually About Clinical Trial Enrollment to People of Color with Lupus
Kreager Taber¹, Holly Milaeger², Jessica Williams¹, Daniel Erickson³, Elmer Freeman⁴, Patricia Canessa⁵, Rosalind Ramsey-Goldman⁶ and Candace Feldman¹, ¹Brigham and Women's Hospital, Boston, MA, ²Northwestern University, Feinberg School of Medicine, Chicago, IL, ³Northwestern University, Feinbergy School of Medicine, Chicago, IL, ⁴CCHERS, Inc., Boston, MA, ⁵State of Illinois Board of Health, Chicago, IL, ⁶Northwestern University, Chicago, IL
Background/Purpose: Despite a disproportionate burden of systemic lupus erythematosus (SLE) and disparities in adverse outcomes among Black compared to white individuals, people of color are…
Abstract Number: 0780 • ACR Convergence 2021
High Adolescent Health Needs and Relationship to Disease in Patients with Childhood-Onset Systemic Lupus Erythematosus
Chelsea DeCoste¹, Paris Moaf¹, Lawrence Ng¹, Dragana Ostojic-Aitkens¹, Fatima Faruq², Byran Maguire³, Deborah Levy¹, Linda Hiraki¹, Alene Toulany¹ and Andrea Knight⁴, ¹The Hospital for Sick Children, Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³Research Institute, The Hospital for Sick Children, Toronto, ON, Canada, ⁴Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: Childhood-onset systemic lupus erythematosus (cSLE), with typical onset in adolescence, is a chronic life-threatening disease. In addition to dealing with cSLE, these adolescents endure…
Abstract Number: 0870 • ACR Convergence 2021
Blood Brain Barrier Integrity and Brain Imaging Patterns in Patients with SLE
Shiran Aharon¹, Dafna Ben-Bashat², Orna Aizenstein³, Moran Artzi⁴, Mark Berman⁵, Victoria Furer⁶, Marina Anouk⁷, Yael Lahat⁸, Jonathan Wollman⁹, Ofir Elalouf⁹, Ari Polachek¹⁰ and Daphna Paran¹¹, ¹Wohl Institute of Advanced Imaging, Tel-Aviv Sourasky Medical Center, Sagol School of Neuroscience, Sackler Faculty of Medicine, Tel-Aviv, Israel, ²Wohl Institute of Advanced Imaging, Tel-Aviv Sourasky Medical Center, Tel-Aviv University, Tel-Aviv, Israel, ³Department of Neuroradiology Tel-Aviv Sourasky Medical Center, Tel-Aviv University, Tel-Aviv, Israel, ⁴Wohl Institute of Advanced Imaging, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel, ⁵Department of Rheumatology , Tel-Aviv Sourasky Medical Center, Tel-Aviv University, Tel Aviv, Israel, ⁶Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ⁷Department of Rheumatology, Tel-Aviv Sourasky Medical Center, Tel-Aviv University, Tel-Aviv, Israel, ⁸Department of Rheumatology , Tel-Aviv Sourasky Medical Center, Tel-Aviv University, Tel-Aviv, Israel, ⁹Tel Aviv Medical Center, Herzliya, Israel, ¹⁰Sourasky Medical Center, Petah-Tikva, Israel, ¹¹Tel Aviv Sourasky Medical Center-Ichilov Hospital, Even Yehuda, Israel
Background/Purpose: The pathogenesis of neuropsychiatric SLE (NPSLE) has not been fully elucidated. Recent evidence suggests impaired blood brain barrier (BBB) integrity as a possible mechanism…
Abstract Number: 0887 • ACR Convergence 2021
Association of Mycophenolate and Azathioprine Use with Cognitive Function in SLE
Chrisanna Dobrowolski¹, Jiandong Su², John McGinley¹, Melissa Fazzari¹, Kathleen Bingham³, Nicole Anderson², Dorcas Beaton⁴, Lesley Ruttan³, Joan Wither², Maria Tartaglia², Mahta Kakvan², Dennisse Bonilla², May Choi⁵, Marvin Fritzler⁶, Patricia Katz⁷, Robin Green², Chaim Putterman¹ and Zahi Touma⁸, ¹Albert Einstein College of Medicine, Bronx, NY, ²University Health Network, Toronto, ON, Canada, ³University of Toronto, University Health Network, Toronto, ON, Canada, ⁴Institute for Work & Health, Toronto, ON, Canada, ⁵Brigham and Women's Hospital | University of Calgary, Calgary, AB, Canada, ⁶University of Calgary, Calgary, AB, Canada, ⁷University of California San Francisco, San Francisco, CA, ⁸University of Toronto, Mississauga, ON, Canada
Background/Purpose: Cognitive dysfunction (CD) is a common manifestation of systemic lupus erythematosus (SLE) which can have detrimental consequences for those affected. To date, no treatments…
Abstract Number: 0988 • ACR Convergence 2021
Risk Prediction Models for Incident Systemic Lupus Erythematosus Using Lifestyle/Environmental Risk Factors and a Genetic Risk Score
Jing Cui¹, Susan Malspeis¹, May Choi², Bing Lu³, Jeffrey Sparks⁴, Kazuki Yoshida⁴ and Karen Costenbader⁵, ¹Brigham Women's Hospital, Boston, MA, ²Brigham and Women's Hospital | University of Calgary, Calgary, AB, Canada, ³Brigham and Women's Hospital and Harvard Medical School, Newton, MA, ⁴Brigham and Women's Hospital, Boston, MA, ⁵Brigham and Women's Hospital, Belmont, MA
Background/Purpose: The identification of lifestyle/environmental and genetic factors, influencing SLE risk introduces the potential to develop risk prediction models. We examined SLE risk prediction incorporating…
Abstract Number: 1152 • ACR Convergence 2021
A Follow-Up Evaluation of a Longstanding Telephone Peer Counseling Service for People with Systemic Lupus Erythematosus and Their Loved Ones
Priscilla Toral, Roberta Horton and Jillian Rose, Hospital for Special Surgery, New York, NY
Background/Purpose: With technology rapidly evolving, studies still reinforce the value of telephone peer support for people living with chronic illness. A follow-up evaluation was conducted…
Abstract Number: 1267 • ACR Convergence 2021
Frailty and Emergency Department Utilization in Systemic Lupus Erythematosus: An Administrative Claims Data Analysis
Sarah Lieber¹, Iris Navarro-Milln², Musarrat Nahid², Mangala Rajan², Sebastian Sattui¹ and Lisa Mandl¹, ¹Hospital for Special Surgery, New York, NY, ²Weill Cornell Medicine, New York, NY
Background/Purpose: Emergency department (ED) utilization is associated with worse quality of care and health-related quality of life (HRQoL) in systemic lupus erythematosus (SLE). While frailty…
Abstract Number: 1283 • ACR Convergence 2021
Reduction in Glucocorticoid Use in Patients with Systemic Lupus Erythematosus Treated with Belimumab: A Large Pooled Analysis of 5 Placebo-Controlled Studies
Karen Costenbader¹, Yoshiyuki Abe², Laurent Arnaud³, George Bertsias⁴, Norma Lynn Fox⁵, Mathew Gibb⁶, Anne Hammer⁵, Alexa Meara⁷, Holly Quasny⁸, David Roth⁵ and Tania Gonzalez-Rivera⁵, ¹Brigham and Women's Hospital, Belmont, MA, ²Juntendo University School of Medicine, Tokyo, Japan, ³Department of Rheumatology, French National Reference Center for Autoimmune Diseases (CRMR RESO), Strasbourg, France, ⁴Rheumatology, Clinical Immunology and Allergy, University of Crete School of Medicine, Heraklion, Greece, ⁵GlaxoSmithKline, Collegeville, PA, ⁶Veramed Ltd., Twickenham, United Kingdom, ⁷Ohio State University Wexner Medical Center, Columbus, OH, ⁸GlaxoSmithKline, Research Triangle Park, NC
Background/Purpose: Glucocorticoids (GC) play an important role in rapid systemic lupus erythematosus (SLE) symptom relief. However, chronic GC use increases organ damage risk; and treatment…
Abstract Number: 1300 • ACR Convergence 2021
Effect of Time in Clinical Remission on Damage Accrual in Systemic Lupus Erythematosus
Konstantinos Tselios¹, Dafna Gladman², Jiandong Su³ and Murray Urowitz⁴, ¹McMaster University, Hamilton, ON, Canada, ²Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ³University Health Network, Toronto, ON, Canada, ⁴Center for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, University of Toronto, Lupus Clinic, Toronto, ON, Canada
Background/Purpose: We have previously shown that prolonged clinical remission for ≥10 years is associated with significantly less damage accrual in inception patients with systemic lupus…
Abstract Number: 1461 • ACR Convergence 2021
Belimumab Improves Renal Responses in Patients with or Without Steroid Pulses During Induction Therapy for Lupus Nephritis
Richard Furie¹, Frédéric Houssiau², Liz Lightstone³, Xueqing Yu⁴, Julia Weinmann-Menke⁵, Yoshiya Tanaka⁶, Angela Jones-Leone⁷, Tania Gonzalez-Rivera⁷, Jennifer Gilbride⁸, Anuradha Madan⁷, Yulia Green⁸ and David Roth⁷, ¹Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ²Cliniques Universitaires Saint-Luc, UCLouvain, Brussels, Belgium, ³Department of Immunology and Inflammation, Imperial College, London, United Kingdom, ⁴Guangdong Provincial People’s Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China (People's Republic), ⁵University Hospital Mainz, Mainz, Germany, ⁶University of Occupational and Environmental Health, Kitakyushu, Japan, ⁷GlaxoSmithKline, Collegeville, PA, ⁸GlaxoSmithKline, Brentford, United Kingdom
Background/Purpose: In the BLISS-LN trial (GSK Study BEL114054; NCT01639339), the administration of belimumab (BEL), a B-lymphocyte stimulator antagonist, resulted in improved renal outcomes in patients…
Abstract Number: 1494 • ACR Convergence 2021
Functional Effects of a Lupus-associated PRKG1 Variant on the RhoA-ROCK Pathway and Response to Type I Interferon
Ruth Fernandez Ruiz¹, Justine Shum², Kayla Van Buren³ and Timothy Niewold⁴, ¹NYU Grossman School of Medicine, New York, NY, ²Marinhealth Medical Center, San Francisco, CA, ³Mnemo Therapeutics, New York, NY, ⁴Colton Center for Autoimmunity NYU School of Medicine, New York, NY
Background/Purpose: Interferon (IFN)-α contributes to susceptibility and severe manifestations in systemic lupus erythematosus (SLE). The PRKG1 rs7897633 variant has been previously identified as the top…
Abstract Number: 1595 • ACR Convergence 2021
Concern About the COVID-19 Pandemic and Community Mobility Among Systemic Lupus Erythematosus Patients
Laura Plantinga¹, Courtney Hoge¹, Cristina Drenkard¹, Charmayne Dunlop-Thomas¹, Brad Pearce¹, S Sam Lim² and C. Barrett Bowling³, ¹Emory University, Atlanta, GA, ²Department of Medicine, Division of Rheumatology, Emory University School of Medicine, Atlanta, GA, ³Duke University, Durham, NC
Background/Purpose: Opportunities for community mobility, which reflects both physical mobility and social participation, during the COVID-19 pandemic have been limited and may have been related…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].